Program Description & Educational Objectives

In this activity, experts on the management of acute myeloid leukemia (AML) discuss factors that may influence more individualized approaches to treatment. They also assess the clinical potential of novel strategies that have modified or begun to move away from conventional cytotoxic-based care while reviewing new data that have supported a more nuanced take on patient management.

Upon completion of this activity, participants will be able to:

• Select appropriate upfront therapy for a younger adult patient with acute myeloid leukemia (AML) based on the patient’s health status, cytogenetic and molecular risk profiles, and disease characteristics
• Develop a treatment plan for older patients with AML who present with untreated disease and who may or may not be eligible for standard therapy
• Recommend individualized therapy for an adult patient with relapsed AML
• Determine the level of risk associated with specific patient and genetic/molecular factors in the AML setting
• Summarize new safety and efficacy data from studies of novel cytotoxic or epigenetic therapy, targeted agents, and other innovative approaches for managing AML

Target Audience

This activity has been designed to meet the educational needs of hematologists, hematologist-oncologists, US advanced practice oncology nurses, pharmacists, and other clinicians involved in the management of adult AML.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no pre-requisites and there is no fee to participate in this activity or to receive CME/CNE/CPE credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Internet
Release and Expiration Dates: December 30, 2011 - December 29, 2012
Time to Complete: 30 minutes

Faculty & Disclosure / Conflict of Interest Policy

All faculty AND staff involved in the planning or presentation of continuing education activities sponsored/provided by Purdue University College of Pharmacy are required to disclose to the audience any real or apparent commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity.

Course Director and Interviewee

Farhad Ravandi-Kashani, MD
Associate Professor
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Farhad Ravandi-Kashani, MD, has a financial interest/relationship or affiliation in the form of:

Grant/Research Support from Bayer HealthCare Pharmaceuticals Inc.; Bristol-Myers Squibb; Celgene Corporation; EMD Serono, Inc.; Incyte Corporation; Onyx Pharmaceuticals, Inc.; and Sunesis Pharmaceuticals, Inc.

Honoraria from Celgene Corporation; Eisai Inc.; and Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Advisory Board for Bayer HealthCare Pharmaceuticals Inc.; Genzyme Corporation; Onyx Pharmaceuticals, Inc.; and Sunesis Pharmaceuticals, Inc.

Interviewee

Gary J. Schiller, MD
Professor, Department of Medicine
Director, Hematological Malignancy Stem Cell Transplantation Program
David Geffen School of Medicine at UCLA
Los Angeles, California

Gary J. Schiller, MD, has a financial interest/relationship or affiliation in the form of:

Grant/Research Support from Abbott Laboratories; Ambit Biosciences Inc.; Bristol-Myers Squibb; Celgene Corporation; Cyclacel Pharmaceuticals, Inc.; Eli Lilly and Company; Genzyme Corporation; GlaxoSmithKline; and Sunesis Pharmaceuticals.

Speakers Bureau participant with Millennium Pharmaceuticals, Inc.

Advisory Board for Sunesis Pharmaceuticals.

Content Director

Carmine DeLuca
PVI, PeerView Institute for Medical Education

Carmine DeLuca currently has no financial interests/relationships or affiliations in relation to this activity.

All additional planning committee members, PVI, PeerView Institute for Medical Education, Inc. staff, and Purdue University College of Pharmacy staff have no relationships to disclose.

Sponsorship, Credit & Support

Physicians

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Purdue University College of Pharmacy and PVI, PeerView Institute for Medical Education. Purdue University College of Pharmacy, an equal access/equal opportunity institution, is accredited by the ACCME to provide continuing medical education for physicians.

The Purdue University College of Pharmacy designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses

Purdue University Continuing Nursing Education, West Lafayette, IN (ISNA No. CNEP 11-03, Exp. 06/1/2014) is an approved provider of continuing nursing education by the Indiana State Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.

This activity has been approved for 0.5 contact hour(s).

Note: Not all state nursing boards will accept programs less than 1.0 hour in length for credit. Please click here to find out the status of your state.

Pharmacists

Purdue University College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This is a knowledge-based, continuing education activity of Purdue University, an equal access/equal opportunity institution. Universal Activity Number (UAN): 0018-9999-11-237-H01-P, 0.5 contact hours (0.05 CEUs).
Release Date: December 30, 2011 Expiration Date: December 29, 2012

This CME/CNE/CPE activity is jointly sponsored by Purdue University College of Pharmacy and PVI, PeerView Institute for Medical Education.

This activity is supported by an educational grant from

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.

Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.